1. Randomised, siteless study to compare systematic atrial fibrillation screening using enrichment by a risk prediction model with standard care in a Swedish population aged ≥ 65 years : CONSIDERING-AF study design
- Author
-
Etminani, Farzaneh, Sandgren, Emma, Holm, Johan, Magnusson, Peter, Modica, Angelo, Moberg, Karin, Davidsson, Thomas, Stalpe, Linda, Kiflemariam, Sara, Younan, Ninia, Parikh, Purvee, Wadhwa, Manish, Sundin, Anna, Engdahl, Johan, Etminani, Farzaneh, Sandgren, Emma, Holm, Johan, Magnusson, Peter, Modica, Angelo, Moberg, Karin, Davidsson, Thomas, Stalpe, Linda, Kiflemariam, Sara, Younan, Ninia, Parikh, Purvee, Wadhwa, Manish, Sundin, Anna, and Engdahl, Johan
- Abstract
INTRODUCTION: Atrial fibrillation (AF) is the most common arrhythmia and confers an increased risk of mortality, stroke, heart failure and cognitive decline. There is growing interest in AF screening; however, the most suitable population and device for AF detection remains to be elucidated. Here, we present the design of the CONSIDERING-AF (deteCtiON and Stroke preventIon by moDEl scRreenING for Atrial Fibrillation) study. METHODS AND ANALYSIS: CONSIDERING-AF is a randomised, controlled, siteless, non-blinded diagnostic superiority trial with four parallel groups and a primary endpoint of identifying AF during a 6-month study period set in Region Halland, Sweden. In each group, 740 individuals aged≥65 years will be included. The primary objective is to compare the intervention of AF screening enrichment using a risk prediction model (RPM), followed by 14 days of a continuous ECG patch, with no intervention (standard care). Primary outcome is defined as the incident AF recorded in the Region Halland Information Database after 6 months as compared with standard care. Secondary endpoints include the difference in incident AF between groups enriched or not by the RPM, with and without an invitation to 14 days of continuous ECG recording, and the proportions of oral anticoagulation treatment in the four groups. ETHICS AND DISSEMINATION: This study has ethical approval from the Swedish Ethical Review Authority. Results will be published in peer-reviewed international journals. TRIAL REGISTRATION NUMBER: NCT05838781. © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ., Funding: Philips/BioTel (NA), Bristol Myers Squibb (NA) & Pfizer (NA)
- Published
- 2024
- Full Text
- View/download PDF